Sandoz Group AG (SDZ) - Net Assets

Latest as of June 2025: CHF8.82 Billion CHF

Based on the latest financial reports, Sandoz Group AG (SDZ) has net assets worth CHF8.82 Billion CHF as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF21.61 Billion) and total liabilities (CHF12.79 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF8.82 Billion
% of Total Assets 40.82%
Annual Growth Rate 4.57%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 4857814.19

Sandoz Group AG - Net Assets Trend (2020–2024)

This chart illustrates how Sandoz Group AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Sandoz Group AG (2020–2024)

The table below shows the annual net assets of Sandoz Group AG from 2020 to 2024.

Year Net Assets Change
2024-12-31 CHF8.16 Billion -5.66%
2023-12-31 CHF8.65 Billion +11218609.08%
2022-12-31 CHF77.14K -100.00%
2021-12-31 CHF7.44 Billion +8.95%
2020-12-31 CHF6.83 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Sandoz Group AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 18.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CHF7.91 Billion 96.88%
Common Stock CHF25.00 Million 0.31%
Other Comprehensive Income CHF231.00 Million 2.83%
Total Equity CHF8.16 Billion 100.00%

Sandoz Group AG Competitors by Market Cap

The table below lists competitors of Sandoz Group AG ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sandoz Group AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 7,276,064,250 to 8,163,000,000, a change of 886,935,750 (12.2%).
  • Net income of 1,000,000 contributed positively to equity growth.
  • Dividend payments of 215,000,000 reduced retained earnings.
  • Share repurchases of 12,000,000 reduced equity.
  • Other comprehensive income decreased equity by 242,848,950.
  • Other factors increased equity by 1,355,784,700.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CHF1.00 Million +0.01%
Dividends Paid CHF215.00 Million -2.63%
Share Repurchases CHF12.00 Million -0.15%
Other Comprehensive Income CHF-242.85 Million -2.97%
Other Changes CHF1.36 Billion +16.61%
Total Change CHF- 12.19%

Book Value vs Market Value Analysis

This analysis compares Sandoz Group AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.57x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 4.24x to 3.57x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2020-12-31 CHF15.82 CHF67.16 x
2021-12-31 CHF17.24 CHF67.16 x
2022-12-31 CHF0.00 CHF67.16 x
2023-12-31 CHF16.87 CHF67.16 x
2024-12-31 CHF18.81 CHF67.16 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sandoz Group AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.01%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.01%
  • • Asset Turnover: 0.46x
  • • Equity Multiplier: 2.44x
  • Recent ROE (0.01%) is above the historical average (-2.28%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2020 6.00% 4.78% 0.54x 2.33x CHF-272.95 Million
2021 11.15% 9.38% 0.55x 2.15x CHF85.51 Million
2022 -29.64% 0.00% 88591.84x 1.30x CHF-30.57K
2023 1.06% 0.77% 0.51x 2.67x CHF-650.61 Million
2024 0.01% 0.01% 0.46x 2.44x CHF-815.30 Million

Industry Comparison

This section compares Sandoz Group AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $249,566,333
  • Average return on equity (ROE) among peers: -6.26%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sandoz Group AG (SDZ) CHF8.82 Billion 6.00% 1.45x $29.43 Billion
CURATIS N AG (CURN) $5.04 Million -20.15% 0.41x $89.64 Million
PolyPeptide Group AG (PPGN) $381.23 Million -13.49% 0.81x $810.06 Million
Siegfried Holding Ltd (SFZN) $362.43 Million 14.86% 0.48x $3.71 Billion

About Sandoz Group AG

SW:SDZ Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$36.57 Billion
CHF28.93 Billion CHF
Market Cap Rank
#797 Global
#9 in Switzerland
Share Price
CHF67.16
Change (1 day)
+2.82%
52-Week Range
CHF32.36 - CHF72.42
All Time High
CHF72.42
About

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage f… Read more